SGLT2抑制剂对糖尿病肾病患者卒中与房颤的影响:CREDENCE试验及荟萃分析
本研究基于CREDENCE试验(4401例2型糖尿病合并慢性肾脏病患者)事后分析及4项大型心血管结局试验的荟萃分析,评估SGLT2抑制剂对卒中及房颤/房扑的影响。CREDENCE中总卒中风险无显著降低(HR 0.77,95%CI 0.55-1.08),但荟萃分析显示出血性卒中(HR 0.50,95%CI 0.30-0.83)和房颤/房扑(HR 0.81,95%CI 0.71-0.93)风险降低,且基线eGFR最低亚组总卒中获益(HR 0.50,95%CI 0.31-0.79)。
要点
- SGLT2抑制剂对总卒中无明确影响,但可能降低出血性卒中风险。
- SGLT2抑制剂与房颤/房扑风险降低相关(HR 0.81)。
- 基线eGFR<45 mL/min/1.73 m²者总卒中获益更明显。
核心结论
- SGLT2抑制剂对总卒中无明确影响,但证据提示可预防出血性卒中、房颤/房扑,且eGFR最低亚组总卒中获益。
研究设计与样本
- CREDENCE试验事后分析纳入4401例2型糖尿病合并慢性肾脏病参与者,随机接受卡格列净或安慰剂。
- 汇总CREDENCE与另外3项已完成的大型SGLT2抑制剂心血管结局试验,采用随机效应荟萃分析。
主要发现
- CREDENCE中142例发生卒中,卡格列净组发生率10.9/1000患者年,安慰剂组14.2/1000患者年,HR 0.77(95%CI 0.55-1.08)。
- CREDENCE卒中亚型:缺血性HR 0.88(95%CI 0.61-1.28,n=111),出血性HR 0.50(95%CI 0.19-1.32,n=18),不明原因HR 0.54(95%CI 0.20-1.46,n=17)。
- CREDENCE中房颤/房扑HR 0.76(95%CI 0.53-1.10,n=115)。
- 4项CVOT汇总:总卒中HR 0.96(95%CI 0.82-1.12),缺血性卒中HR 1.01(95%CI 0.89-1.14),出血性卒中HR 0.50(95%CI 0.30-0.83),不明原因卒中HR 0.86(95%CI 0.49-1.51),房颤/房扑HR 0.81(95%CI 0.71-0.93)。
- SGLT2抑制剂对总卒中的效应随基线eGFR变化(P=0.01),eGFR最低亚组(<45 mL/min/1.73 m²)HR 0.50(95%CI 0.31-0.79)。
关键数值与推荐
- CREDENCE中卒中定义为致死性或非致死性卒中,并分析卒中亚型及房颤/房扑等中间标志物。
- 荟萃分析纳入CREDENCE及3项其他大型SGLT2抑制剂心血管结局试验的卒中和房颤/房扑数据。
临床怎么用
- 对于2型糖尿病合并慢性肾脏病患者,SGLT2抑制剂可能有助于降低出血性卒中和房颤/房扑风险。
- 基线eGFR<45 mL/min/1.73 m²的患者使用SGLT2抑制剂可能获得更明显的总卒中预防获益。
- 临床决策时应结合患者肾功能和卒中风险个体化评估SGLT2抑制剂的获益。
局限性
- CREDENCE中卒中事件数较少,亚型分析置信区间宽。
- 卒中及房颤/房扑分析为事后分析,需前瞻性研究验证。
- 荟萃分析仅纳入4项大型CVOT,可能受各试验人群和设计差异影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Chronic kidney disease with reduced estimated glomerular filtration rate or elevated albuminuria increases risk for ischemic and hemorrhagic stroke. This study assessed the effects of sodium glucose cotransporter 2 inhibitors (SGLT2i) on stroke and atrial fibrillation/flutter (AF/AFL) from CREDENCE (Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation) and a meta-analysis of large cardiovascular outcome trials (CVOTs) of SGLT2i in type 2 diabetes mellitus. METHODS: CREDENCE randomized 4401 participants with type 2 diabetes mellitus and chronic kidney disease to canagliflozin or placebo. Post hoc, we estimated effects on fatal or nonfatal stroke, stroke subtypes, and intermediate markers of stroke risk including AF/AFL. Stroke and AF/AFL data from 3 other completed large CVOTs and CREDENCE were pooled using random-effects meta-analysis. RESULTS: In CREDENCE, 142 participants experienced a stroke during follow-up (10.9/1000 patient-years with canagliflozin, 14.2/1000 patient-years with placebo; hazard ratio [HR], 0.77 [95% CI, 0.55-1.08]). Effects by stroke subtypes were: ischemic (HR, 0.88 [95% CI, 0.61-1.28]; n=111), hemorrhagic (HR, 0.50 [95% CI, 0.19-1.32]; n=18), and undetermined (HR, 0.54 [95% CI, 0.20-1.46]; n=17). There was no clear effect on AF/AFL (HR, 0.76 [95% CI, 0.53-1.10]; n=115). The overall effects in the 4 CVOTs combined were: total stroke (HRpooled, 0.96 [95% CI, 0.82-1.12]), ischemic stroke (HRpooled, 1.01 [95% CI, 0.89-1.14]), hemorrhagic stroke (HRpooled, 0.50 [95% CI, 0.30-0.83]), undetermined stroke (HRpooled, 0.86 [95% CI, 0.49-1.51]), and AF/AFL (HRpooled, 0.81 [95% CI, 0.71-0.93]). There was evidence that SGLT2i effects on total stroke varied by baseline estimated glomerular filtration rate (P=0.01), with protection in the lowest estimated glomerular filtration rate (<45 mL/min/1.73 m2]) subgroup (HRpooled, 0.50 [95% CI, 0.31-0.79]). CONCLUSIONS: Although we found no clear effect of SGLT2i on total stroke in CREDENCE or across trials combined, there was some evidence of benefit in preventing hemorrhagic stroke and AF/AFL, as well as total stroke for those with lowest estimated glomerular filtration rate. Future research should focus on confirming these data and exploring potential mechanisms. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02065791.
引用
- Zhou Z, Jardine MJ, Li Q, et al. Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease: Results From the CREDENCE Trial and Meta-Analysis. Stroke. 2021. PMID: 33874750. doi:10.1161/STROKEAHA.120.031623
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。